Mercury Bio Joins the Alliance for mRNA Medicines

Novel Oral and IV Drug Delivery Platform Can Enable Faster and Lower Cost Development with Broad Biodistribution of Nucleic Acids, Proteins and Small Molecule Drugs

Mercury Bio, a Santa Fe, NM-based biotech company commercializing an innovative and highly disruptive drug delivery platform, today announced that it has joined the Alliance for mRNA Medicines as a charter member, and that Chief Science Officer Richard Sayre, Ph.D. has joined the Alliance for mRNA Medicines (AMM) board.

Clay Alspach, Executive Director of AMM, commented, “We are thrilled to have Mercury Bio join our august group of leading biotechs, pharma companies, academic institutions, and non-profits developing and supporting the next generation of mRNA medicines. We look forward to their scientific contributions in a shared vision of enabling broad access of novel nucleic acid therapeutics for patients around the world.”

Bruce McCormick, Mercury Bio CEO, remarked, “Our team has created a drug delivery platform that has demonstrated successful oral and IV delivery of nucleic acids, which can reach all organs of the body, including the brain. Our proprietary, non-animal, non-human drug delivery platform—an alternative to lipid nanoparticles (LNP)—is based on the bioengineering and production of yeast-derived extracellular vesicles (yEV™). Dr. Sayre leads our scientific team, comprised of world-class experts in exosomes, microbial genetics, molecular and computational biology and bioinformatics. We are excited to partner with AMM to advance the development of novel nucleic acid therapeutics.”

SourcePR Newswire

Leave a Reply

Your email address will not be published. Required fields are marked *